One of the popular terms in pharmaceutical manufacturing is flexibility. This is not a traditional core competence of the pharmaceutical industry, where regulatory requirements and regulatory compliance have been easy excuses for slow changes or no changes. Gert Moelgaard, Novo Nordisk and NNE, looks at the need for pharmaceutical companies to show willingness to change and demonstrate manufacturing, networks and partnerships that point to the next generation of pharmaceutical manufacturing.

Comments are closed.

%d bloggers like this: